These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22147810)

  • 41. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.
    Thomasius R; Petersen K; Buchert R; Andresen B; Zapletalova P; Wartberg L; Nebeling B; Schmoldt A
    Psychopharmacology (Berl); 2003 Apr; 167(1):85-96. PubMed ID: 12632248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users.
    Roberts CA; Jones A; Montgomery C
    Neurosci Biobehav Rev; 2016 Apr; 63():158-67. PubMed ID: 26855234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic treatment with a serotonin(2) receptor (5-HT(2)R) agonist modulates the behavioral and cellular response to (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA].
    Ross JD; Herin DV; Frankel PS; Thomas ML; Cunningham KA
    Drug Alcohol Depend; 2006 Feb; 81(2):117-27. PubMed ID: 16054778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women.
    Moses-Kolko EL; Berga SL; Greer PJ; Smith G; Cidis Meltzer C; Drevets WC
    Fertil Steril; 2003 Sep; 80(3):554-9. PubMed ID: 12969697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients.
    Erritzoe D; Rasmussen H; Kristiansen KT; Frokjaer VG; Haugbol S; Pinborg L; Baaré W; Svarer C; Madsen J; Lublin H; Knudsen GM; Glenthoj BY
    Neuropsychopharmacology; 2008 Sep; 33(10):2435-41. PubMed ID: 18288096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Executive function in abstinent MDMA ('ecstasy') users.
    Zakzanis KK; Young DA
    Med Sci Monit; 2001; 7(6):1292-8. PubMed ID: 11687745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users.
    Frokjaer VG; Erritzoe D; Holst KK; Madsen KS; Fisher PM; Madsen J; Svarer C; Knudsen GM
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1119-28. PubMed ID: 24524290
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine ("Ecstasy")/polydrug users.
    Burgess AP; Venables L; Jones H; Edwards R; Parrott AC
    Psychopharmacology (Berl); 2011 Aug; 216(4):545-56. PubMed ID: 21390504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy") users.
    Chang L; Ernst T; Grob CS; Poland RE
    J Magn Reson Imaging; 1999 Oct; 10(4):521-6. PubMed ID: 10508318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.
    Vegting Y; Reneman L; Booij J
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3473-501. PubMed ID: 27568200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems.
    Parrott AC; Milani RM; Parmar R; Turner JD
    Psychopharmacology (Berl); 2001 Dec; 159(1):77-82. PubMed ID: 11797073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serotonin transporter availability, neurocognitive function and their correlation in abstinent 3,4-methylenedioxymethamphetamine users.
    van de Blaak FL; Dumont GJH
    Hum Psychopharmacol; 2022 Jan; 37(1):e2811. PubMed ID: 34506649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons.
    Capela JP; Fernandes E; Remião F; Bastos ML; Meisel A; Carvalho F
    Neurotoxicology; 2007 Jul; 28(4):868-75. PubMed ID: 17572501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system.
    White SR; Obradovic T; Imel KM; Wheaton MJ
    Prog Neurobiol; 1996 Aug; 49(5):455-79. PubMed ID: 8895996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study.
    Chang L; Grob CS; Ernst T; Itti L; Mishkin FS; Jose-Melchor R; Poland RE
    Psychiatry Res; 2000 Feb; 98(1):15-28. PubMed ID: 10708923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroimaging of chronic MDMA ("ecstasy") effects: A meta-analysis.
    Müller F; Brändle R; Liechti ME; Borgwardt S
    Neurosci Biobehav Rev; 2019 Jan; 96():10-20. PubMed ID: 30439373
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discrete memory impairments in largely pure chronic users of MDMA.
    Wunderli MD; Vonmoos M; Fürst M; Schädelin K; Kraemer T; Baumgartner MR; Seifritz E; Quednow BB
    Eur Neuropsychopharmacol; 2017 Oct; 27(10):987-999. PubMed ID: 28866005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence.
    Dafters RI; Duffy F; O'Donnell PJ; Bouquet C
    Psychopharmacology (Berl); 1999 Jul; 145(1):82-90. PubMed ID: 10445376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.